Literature DB >> 10617300

Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype.

J M Garcia1, J M Silva, G Dominguez, R Gonzalez, A Navarro, L Carretero, M Provencio, P España, F Bonilla.   

Abstract

Loss of heterozygosity (LOH) in loci of the 10q23 region that harbor the PTEN gene and mutations in the sequence of this gene have been found in several primary human tumors including breast carcinomas, suggesting that this gene could be implicated in their pathogenesis. We investigated allelic losses in microsatellites of the 10q23 region, and their correlations with nine pathologic parameters in 105 breast carcinomas. The LOH analysis was performed by amplifying DNA by PCR, using five markers of the 10q23 region (D10S1687, D10S541, D10S2491, D10S583 and D10S571). LOH in at least one marker of the PTEN region was found in 29.5% of tumors. The statistical comparison between carcinomas with and without LOH in terms of the pathologic parameters showed significant differences in age (p = 0.03), lymph node metastases (p = 0.02), and higher histological grade (p = 0.02); a trend toward significance was found for progesterone receptors (p = 0.05). LOH in an individual marker and statistically significant relationships to tumor characteristics were observed at locus D10S541 for lymph node metastases (p = 0.04), at D10S2491 (intragenic to the PTEN gene) for lymph node metastases (p = 0.02), and at D10S583 for progesterone receptors (p = 0.01) and for high grade (p = 0.03). These results suggest the PTEN gene, or other genes of the 10q23 region, could be functionally related to breast cancer, probably influencing the development of histological features associated with poor prognosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10617300     DOI: 10.1023/a:1006273516976

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  30 in total

1.  Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.

Authors:  Ping Li; Artour Torossian; Qing Zhang; Wen-Cai Xu; Shen Fu
Journal:  Med Oncol       Date:  2012-06-23       Impact factor: 3.064

2.  Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells.

Authors:  Michele I Vitolo; Michele B Weiss; Marta Szmacinski; Khola Tahir; Todd Waldman; Ben Ho Park; Stuart S Martin; David J Weber; Kurtis E Bachman
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

3.  The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients.

Authors:  Nikola Tanic; Zorka Milovanovic; Nasta Tanic; Radan Dzodic; Zorica Juranic; Snezana Susnjar; Vesna Plesinac-Karapandzic; Svetislav Tatic; Tatjana Dramicanin; Radoslav Davidovic; Bogomir Dimitrijevic
Journal:  Cancer Biol Ther       Date:  2012-08-15       Impact factor: 4.742

4.  Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.

Authors:  Chad J Creighton; Xiaoyong Fu; Bryan T Hennessy; Angelo J Casa; Yiqun Zhang; Ana Maria Gonzalez-Angulo; Ana Lluch; Joe W Gray; Powell H Brown; Susan G Hilsenbeck; C Kent Osborne; Gordon B Mills; Adrian V Lee; Rachel Schiff
Journal:  Breast Cancer Res       Date:  2010-06-22       Impact factor: 6.466

5.  Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest.

Authors:  Emily A Nizialek; Charissa Peterson; Jessica L Mester; Erinn Downes-Kelly; Charis Eng
Journal:  Hum Mol Genet       Date:  2013-02-27       Impact factor: 6.150

6.  The molecular genetics of breast cancer and targeted therapy.

Authors:  Rachel Suter; James A Marcum
Journal:  Biologics       Date:  2007-09

7.  Molecular cytogenetic investigations of synchronous bilateral breast cancer.

Authors:  K Agelopoulos; N Tidow; E Korsching; R Voss; B Hinrichs; B Brandt; W Boecker; H Buerger
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

8.  A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

Authors:  Neil E Torbett; Antonio Luna-Moran; Zachary A Knight; Andrew Houk; Mark Moasser; William Weiss; Kevan M Shokat; David Stokoe
Journal:  Biochem J       Date:  2008-10-01       Impact factor: 3.857

9.  PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.

Authors:  Babette Schade; Trisha Rao; Nathalie Dourdin; Robert Lesurf; Michael Hallett; Robert D Cardiff; William J Muller
Journal:  J Biol Chem       Date:  2009-05-12       Impact factor: 5.157

Review 10.  Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy.

Authors:  Justin Cidado; Ben Ho Park
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-08-04       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.